AC
EFTR

Armistice Capital’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Armistice Capital’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-223,000
Closed -$3.21M – 402
2024
Q1 		$3.21M Buy
+223,000
New +$2.67M 0.04% 134

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Armistice Capital's EFTR Position: Q2 2024 in Review

Armistice Capital sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q2 2024, closing a stake of 223,000 shares — an estimated $3.21M sold.

Armistice Capital first reported a position in EFTR in Q1 2024 and held it in 1 quarter. The position peaked at $3.21M in Q1 2024. 18 funds tracked by Wall St. Rank hold EFTR as of Q2 2024.

  • Armistice Capital reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Armistice Capital sold 223,000 eFFECTOR Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $3.21M.
  • Armistice Capital first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Armistice Capital's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $3.21M in Q1 2024.
  • 18 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Armistice Capital's 13F filing for Q2 2024, filed 14 Aug 2024.